Severe acute dystonia induced by ondansetron in a paediatric patient: a case report
Abstract
Ondansetron, a 5-HT3 serotonin receptor antagonist, is widely used to manage nausea and vomiting, particularly in postoperative recovery, chemotherapy, and paediatric gastroenteritis. Although it is well-tolerated, recent reports have raised concerns regarding dystonic reactions associated with its use, particularly in children. A 9-year-old boy (24 kg) developed acute dystonia after receiving a 2mg intravenous dose of ondansetron followed by a 4mg oral dose for symptomatic relief of acute gastroenteritis. Several hours post-administration, he exhibited abnormal muscle movement. Clinical examination showed dystonia and a positive Babinski’s sign. The patient was diagnosed with ondansetron-induced acute dystonia and was successfully treated with oral trihexyphenidyl and clonazepam. Emerging evidence indicates that ondansetron may disrupt dopaminergic-cholinergic balance in the basal ganglia, potentially triggering dystonic reactions. The Naranjo scale classified this reaction as “probable”, further supporting ondansetron as the causative agent. Although rare, dystonic reactions can occur with ondansetron, especially in paediatric populations. Clinicians should remain vigilant when prescribing ondansetron, especially in children.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.